Beginning today (October 25th), the National Health Insurance is applied to COVID-19 treatments, Paxlovid Tab (Pfizer Korea) and Veklury Inj (Gilead Sciences Korea).

The patient copay will be maintained at the current cost of about KRW 50,000: KRW 47,090 for a single package of Paxlovid Tab (30 tablets) and KRW 49,920 (6 bottles) for Veklury Inj.

The government expects that the National Health Insurance reimbursement will enable a stable supply of the COVID-19 treatments on a needs basis.

Previously, the Korea Disease Control and Prevention Agency (KDCA) had purchased the drugs from pharmaceutical companies and distributed them to pharmacies at no cost. It will transition